Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirbanibulin - Almirall

Next Previous
X
Search
Drug Profile

Tirbanibulin - Almirall

Alternative Names: ALM-14789; KLISYRI; Klisyri; KX-01; KX-2391

Latest Information Update: 26 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Almirall S.A.; Athenex; Hanmi Pharmaceutical; Kinex Pharmaceuticals; PharmaEssentia Corporation
  • Class Acetamides; Antineoplastics; Antipsoriatics; Morpholines; Phenyl ethers; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Src-family kinase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Psoriasis
  • Phase I/II Solid tumours
  • No development reported Prostate cancer
  • Discontinued Acute myeloid leukaemia; Photodamage; Skin cancer

Most Recent Events

  • 10 Jun 2024 US FDA approves sNDA for tirbanibulin for Actinic keratosis
  • 08 Mar 2024 Efficacy data from a phase III trial in Keratosis presented at the American Academy of Dermatology annual Meeting 2024 (AAD-2024)
  • 28 Feb 2024 No recent reports of development identified for preclinical development in Skin-cancer in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top